Revolution Medicines, Inc. Share Price
RVMDRevolution Medicines, Inc. Stock Performance
Open $143.25 | Prev. Close $140.34 | Circuit Range N/A |
Day Range $139.25 - $143.25 | Year Range $34.22 - $155.52 | Volume 35,787 |
Average Traded $141.05 |
Revolution Medicines, Inc. Share Price Chart
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Revolution Medicines, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
28-Apr-26 | $145.88 | $144.80 | +9.89% |
27-Apr-26 | $137.04 | $131.77 | -2.61% |
24-Apr-26 | $134.55 | $135.30 | +0.80% |
23-Apr-26 | $142.55 | $134.23 | -5.11% |
22-Apr-26 | $149.56 | $141.46 | -4.96% |
21-Apr-26 | $147.68 | $148.85 | +1.78% |
20-Apr-26 | $151.84 | $146.24 | -1.63% |